Skip to main content
Erschienen in: World Journal of Surgery 3/2018

06.09.2017 | Original Scientific Report

Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study

verfasst von: Xu-Feng Zhang, Jeffery Chakedis, Fabio Bagante, Eliza W. Beal, Yi Lv, Matthew Weiss, Irinel Popescu, Hugo P. Marques, Luca Aldrighetti, Shishir K. Maithel, Carlo Pulitano, Todd W. Bauer, Feng Shen, George A. Poultsides, Oliver Soubrane, Guillaume Martel, B. Groot Koerkamp, Alfredo Guglielmi, Endo Itaru, Timothy M. Pawlik

Erschienen in: World Journal of Surgery | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

We sought to investigate the prognosis of patients following curative-intent surgery for intrahepatic cholangiocarcinoma (ICC) stratified by hepatitis B (HBV-ICC), hepatolithiasis (Stone-ICC), and no identifiable cause (conventional ICC) etiologic subtype.

Methods

986 patients with HBV-ICC (n = 201), stone-ICC (n = 103), and conventional ICC (n = 682) who underwent curative-intent resection were identified from a multi-institutional database. Propensity score matching (PSM) was used to mitigate residual bias.

Results

HBV-ICC patients more often had cirrhosis, earlier stage tumors, a mass-forming lesion, well-to-moderate tumor differentiation, and an R0 resection versus stone-ICC or conventional ICC patients. Five-year recurrence-free survival among HBV-ICC and conventional ICC patients was 23.9 and 17.8%, respectively, versus a recurrence-free of only 8.3% among patients with stone-ICC. Similarly, 5-year overall survival among patients with stone-ICC was only 18.3% compared with 48.9 and 38.0% for patients with HBV-ICC and conventional ICC, respectively. On PSM, patients with stone-ICC group had equivalent long-term outcomes as HBV-ICC patients. In contrast, on PSM, stone-ICC patients had a median overall survival of only 18.0 months versus 44.0 months for patients with conventional ICC. Median overall survival after intrahepatic-only recurrence among patients who had stone-ICC (6.0 months) was worse than OS among HBV-ICC (13.0 months) or conventional ICC (12.0 months) (p = 0.006 and p = 0.082, respectively).

Conclusions

While HBV-ICC had a better prognosis on unadjusted analyses, these differences were mitigated on PSM suggesting no stage-for-stage differences in outcomes compared with stone-ICC or conventional ICC. In contrast, patients with stone-ICC had worse long-term outcomes. These data highlight the relative importance of ICC etiology relative to established clinicopathological factors in the prognosis of patients with ICC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Aljiffry M, Abdulelah A, Walsh M et al (2009) Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 208:134–147CrossRefPubMed Aljiffry M, Abdulelah A, Walsh M et al (2009) Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 208:134–147CrossRefPubMed
2.
Zurück zum Zitat Khan SA, Toledano MB, Taylor-Robinson SD (2008) Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 10:77–82CrossRef Khan SA, Toledano MB, Taylor-Robinson SD (2008) Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 10:77–82CrossRef
3.
Zurück zum Zitat Saha SK, Zhu AX, Fuchs CS et al (2016) Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise. Oncologist 21:594–599CrossRefPubMedPubMedCentral Saha SK, Zhu AX, Fuchs CS et al (2016) Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise. Oncologist 21:594–599CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Shin HR, Oh JK, Masuyer E et al (2010) Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma–focus on East and South-Eastern Asia. Asian Pac J Cancer Prev 11:1159–1166PubMed Shin HR, Oh JK, Masuyer E et al (2010) Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma–focus on East and South-Eastern Asia. Asian Pac J Cancer Prev 11:1159–1166PubMed
6.
Zurück zum Zitat Brito AF, Abrantes AM, Encarnacao JC et al (2015) Cholangiocarcinoma: from molecular biology to treatment. Med Oncol 32:245CrossRefPubMed Brito AF, Abrantes AM, Encarnacao JC et al (2015) Cholangiocarcinoma: from molecular biology to treatment. Med Oncol 32:245CrossRefPubMed
7.
Zurück zum Zitat Dodson RM, Weiss MJ, Cosgrove D et al (2013) Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg 217(736–750):e734 Dodson RM, Weiss MJ, Cosgrove D et al (2013) Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg 217(736–750):e734
8.
Zurück zum Zitat Anderson CD, Pinson CW, Berlin J et al (2004) Diagnosis and treatment of cholangiocarcinoma. Oncologist 9(43–5):7 Anderson CD, Pinson CW, Berlin J et al (2004) Diagnosis and treatment of cholangiocarcinoma. Oncologist 9(43–5):7
9.
Zurück zum Zitat Ben-Menachem T (2007) Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol 19:615–617CrossRefPubMed Ben-Menachem T (2007) Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol 19:615–617CrossRefPubMed
11.
Zurück zum Zitat Spolverato G, Vitale A, Cucchetti A et al (2015) Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer 121:3998–4006CrossRefPubMed Spolverato G, Vitale A, Cucchetti A et al (2015) Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer 121:3998–4006CrossRefPubMed
12.
Zurück zum Zitat Weber SM, Jarnagin WR, Klimstra D et al (2001) Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 193:384–391CrossRefPubMed Weber SM, Jarnagin WR, Klimstra D et al (2001) Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 193:384–391CrossRefPubMed
13.
Zurück zum Zitat Amini N, Ejaz A, Spolverato G et al (2014) Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol 110:163–170CrossRefPubMed Amini N, Ejaz A, Spolverato G et al (2014) Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol 110:163–170CrossRefPubMed
14.
Zurück zum Zitat Mavros MN, Economopoulos KP, Alexiou VG et al (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149:565–574CrossRefPubMed Mavros MN, Economopoulos KP, Alexiou VG et al (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149:565–574CrossRefPubMed
15.
Zurück zum Zitat Spolverato G, Kim Y, Alexandrescu S et al (2016) Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol 23:235–243CrossRefPubMed Spolverato G, Kim Y, Alexandrescu S et al (2016) Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol 23:235–243CrossRefPubMed
16.
Zurück zum Zitat Wang Q, Li J, Lei Z et al (2017) Prognosis of intrahepatic cholangiocarcinomas with HBV infection is better than those with hepatolithiasis after R0 liver resection: a propensity score matching analysis. Ann Surg Oncol 24:1579–1587CrossRefPubMed Wang Q, Li J, Lei Z et al (2017) Prognosis of intrahepatic cholangiocarcinomas with HBV infection is better than those with hepatolithiasis after R0 liver resection: a propensity score matching analysis. Ann Surg Oncol 24:1579–1587CrossRefPubMed
17.
Zurück zum Zitat Ahn CS, Hwang S, Lee YJ et al (2016) Prognostic impact of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma. ANZ J Surg. doi:10.1111/ans.13753 Ahn CS, Hwang S, Lee YJ et al (2016) Prognostic impact of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma. ANZ J Surg. doi:10.​1111/​ans.​13753
18.
Zurück zum Zitat Zhang L, Cai JQ, Zhao JJ et al (2010) Impact of hepatitis B virus infection on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 101:233–238CrossRefPubMed Zhang L, Cai JQ, Zhao JJ et al (2010) Impact of hepatitis B virus infection on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 101:233–238CrossRefPubMed
19.
Zurück zum Zitat Wakabayashi H, Hashimoto N, Okano K et al (2008) Clinicopathological comparison between intrahepatic cholangiocarcinoma arising in livers positive and negative for hepatitis B or C virus. Liver Int 28:717–718CrossRefPubMed Wakabayashi H, Hashimoto N, Okano K et al (2008) Clinicopathological comparison between intrahepatic cholangiocarcinoma arising in livers positive and negative for hepatitis B or C virus. Liver Int 28:717–718CrossRefPubMed
20.
Zurück zum Zitat Horino K, Beppu T, Komori H et al (2012) Evaluation of mass-forming intrahepatic cholangiocarcinoma with viral hepatitis. Hepatogastroenterology 59:1217–1219PubMed Horino K, Beppu T, Komori H et al (2012) Evaluation of mass-forming intrahepatic cholangiocarcinoma with viral hepatitis. Hepatogastroenterology 59:1217–1219PubMed
21.
Zurück zum Zitat Ariizumi S, Kotera Y, Takahashi Y et al (2011) Mass-forming intrahepatic cholangiocarcinoma with marked enhancement on arterial-phase computed tomography reflects favorable surgical outcomes. J Surg Oncol 104:130–139CrossRefPubMed Ariizumi S, Kotera Y, Takahashi Y et al (2011) Mass-forming intrahepatic cholangiocarcinoma with marked enhancement on arterial-phase computed tomography reflects favorable surgical outcomes. J Surg Oncol 104:130–139CrossRefPubMed
22.
Zurück zum Zitat Su CH, Shyr YM, Lui WY et al (1997) Hepatolithiasis associated with cholangiocarcinoma. Br J Surg 84:969–973CrossRefPubMed Su CH, Shyr YM, Lui WY et al (1997) Hepatolithiasis associated with cholangiocarcinoma. Br J Surg 84:969–973CrossRefPubMed
23.
Zurück zum Zitat Chen MF, Jan YY, Jeng LB et al (1999) Intrahepatic cholangiocarcinoma in Taiwan. J Hepatobiliary Pancreat Surg 6:136–141CrossRefPubMed Chen MF, Jan YY, Jeng LB et al (1999) Intrahepatic cholangiocarcinoma in Taiwan. J Hepatobiliary Pancreat Surg 6:136–141CrossRefPubMed
24.
Zurück zum Zitat Liu RQ, Shen SJ, Hu XF et al (2013) Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors. Cancer Cell Int 13:99CrossRefPubMedPubMedCentral Liu RQ, Shen SJ, Hu XF et al (2013) Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors. Cancer Cell Int 13:99CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Edge SBD, Compton CC, Fritz AG, Greene FL (2010) Trotti A AJCC Cancer Staging Manual, 7th edn. Springer, New York Edge SBD, Compton CC, Fritz AG, Greene FL (2010) Trotti A AJCC Cancer Staging Manual, 7th edn. Springer, New York
26.
Zurück zum Zitat Chang KY, Chang JY (2009) Yen Y Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw 7:423–427CrossRefPubMed Chang KY, Chang JY (2009) Yen Y Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw 7:423–427CrossRefPubMed
27.
Zurück zum Zitat El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142(1264–1273):e1261 El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142(1264–1273):e1261
28.
Zurück zum Zitat Zhou H, Wang H, Zhou D et al (2010) Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. Eur J Cancer 46:1056–1061CrossRefPubMed Zhou H, Wang H, Zhou D et al (2010) Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. Eur J Cancer 46:1056–1061CrossRefPubMed
29.
Zurück zum Zitat Palmer WC (2012) Patel T Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 57:69–76CrossRefPubMedPubMedCentral Palmer WC (2012) Patel T Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 57:69–76CrossRefPubMedPubMedCentral
30.
31.
Zurück zum Zitat Wilkens L, Bredt M, Flemming P et al (2000) Differentiation of multicentric origin from intra-organ metastatic spread of hepatocellular carcinomas by comparative genomic hybridization. J Pathol 192:43–51CrossRefPubMed Wilkens L, Bredt M, Flemming P et al (2000) Differentiation of multicentric origin from intra-organ metastatic spread of hepatocellular carcinomas by comparative genomic hybridization. J Pathol 192:43–51CrossRefPubMed
33.
Zurück zum Zitat Zhou XD, Tang ZY, Fan J et al (2009) Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 135:1073–1080CrossRefPubMed Zhou XD, Tang ZY, Fan J et al (2009) Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 135:1073–1080CrossRefPubMed
34.
Zurück zum Zitat Wu ZF, Yang N, Li DY et al (2013) Characteristics of intrahepatic cholangiocarcinoma in patients with hepatitis B virus infection: clinicopathologic study of resected tumours. J Viral Hepat 20:306–310CrossRefPubMed Wu ZF, Yang N, Li DY et al (2013) Characteristics of intrahepatic cholangiocarcinoma in patients with hepatitis B virus infection: clinicopathologic study of resected tumours. J Viral Hepat 20:306–310CrossRefPubMed
35.
Zurück zum Zitat Bagante F, Spolverato G, Weiss M et al (2017) Impact of morphological status on long-term outcome among patients undergoing liver surgery for intrahepatic cholangiocarcinoma. Ann Surg Oncol 24:2491–2501CrossRefPubMed Bagante F, Spolverato G, Weiss M et al (2017) Impact of morphological status on long-term outcome among patients undergoing liver surgery for intrahepatic cholangiocarcinoma. Ann Surg Oncol 24:2491–2501CrossRefPubMed
36.
Zurück zum Zitat Shirabe K, Mano Y, Taketomi A et al (2010) Clinicopathological prognostic factors after hepatectomy for patients with mass-forming type intrahepatic cholangiocarcinoma: relevance of the lymphatic invasion index. Ann Surg Oncol 17:1816–1822CrossRefPubMed Shirabe K, Mano Y, Taketomi A et al (2010) Clinicopathological prognostic factors after hepatectomy for patients with mass-forming type intrahepatic cholangiocarcinoma: relevance of the lymphatic invasion index. Ann Surg Oncol 17:1816–1822CrossRefPubMed
37.
Zurück zum Zitat Chen MF, Jan YY, Hwang TL et al (2000) Impact of concomitant hepatolithiasis on patients with peripheral cholangiocarcinoma. Dig Dis Sci 45:312–316CrossRefPubMed Chen MF, Jan YY, Hwang TL et al (2000) Impact of concomitant hepatolithiasis on patients with peripheral cholangiocarcinoma. Dig Dis Sci 45:312–316CrossRefPubMed
38.
Zurück zum Zitat Guglielmi A, Ruzzenente A, Valdegamberi A et al (2014) Hepatolithiasis-associated cholangiocarcinoma: results from a multi-institutional national database on a case series of 23 patients. Eur J Surg Oncol 40:567–575CrossRefPubMed Guglielmi A, Ruzzenente A, Valdegamberi A et al (2014) Hepatolithiasis-associated cholangiocarcinoma: results from a multi-institutional national database on a case series of 23 patients. Eur J Surg Oncol 40:567–575CrossRefPubMed
39.
Zurück zum Zitat Lee CC, Wu CY, Chen GH (2002) What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? J Gastroenterol Hepatol 17:1015–1020CrossRefPubMed Lee CC, Wu CY, Chen GH (2002) What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? J Gastroenterol Hepatol 17:1015–1020CrossRefPubMed
40.
Zurück zum Zitat Liau JY, Tsai JH, Yuan RH et al (2014) Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol 27:1163–1173CrossRefPubMed Liau JY, Tsai JH, Yuan RH et al (2014) Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol 27:1163–1173CrossRefPubMed
41.
Zurück zum Zitat Wang P, Dong Q, Zhang C et al (2013) Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32(25):3091CrossRefPubMed Wang P, Dong Q, Zhang C et al (2013) Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32(25):3091CrossRefPubMed
42.
Zurück zum Zitat Sia D, Hoshida Y, Villanueva A et al (2013) Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144:829–840CrossRefPubMedPubMedCentral Sia D, Hoshida Y, Villanueva A et al (2013) Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144:829–840CrossRefPubMedPubMedCentral
Metadaten
Titel
Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study
verfasst von
Xu-Feng Zhang
Jeffery Chakedis
Fabio Bagante
Eliza W. Beal
Yi Lv
Matthew Weiss
Irinel Popescu
Hugo P. Marques
Luca Aldrighetti
Shishir K. Maithel
Carlo Pulitano
Todd W. Bauer
Feng Shen
George A. Poultsides
Oliver Soubrane
Guillaume Martel
B. Groot Koerkamp
Alfredo Guglielmi
Endo Itaru
Timothy M. Pawlik
Publikationsdatum
06.09.2017
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 3/2018
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-4199-9

Weitere Artikel der Ausgabe 3/2018

World Journal of Surgery 3/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.